Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderately or highly emetogenic chemotherapy (LEC/MEC/HEC)

References

• Berger AM, Clark-Snow RA. Nausea and vomiting. In: Cancer: Principles & Practice in Oncology, 6th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2001
   Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Antiemesis. V.2.2010. [Last accessed 6 October 2010]
   Google Scholar
• Bloechl-Daum B, Deuson RR, Mavros P, et al. Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 2006;24:4472-8
   PubMed Web of Science ®Google Scholar
• Ihbe-Heffinger A, Ehlken B, Bernard R, et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 2004;15:526-36
   PubMed Web of Science ®Google Scholar
• Feinberg BA, Gilmore J, Haislip S, et al. Data-driven medical decision-making in managing chemotherapy-induced nausea and vomiting. Comm Oncol 2009;6:62-7
   Google Scholar
• Lindley CM, Hirsch JD, O’Neill CV, et al. Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1992;1:331-40
   PubMedGoogle Scholar
• Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008;358:2482-94
   PubMed Web of Science ®Google Scholar
• Sun CC, Bodurka DC, Weaver CB, et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 2005;13:219-27
   PubMed Web of Science ®Google Scholar
• Shih Y-CT, Xu Y, Etling LS. Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer 2007;110:678-85
   PubMed Web of Science ®Google Scholar
• Grunberg SM, Osoba D, Hesketh PJ, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity – an update. Support Care Cancer 2005;13:80-4
   PubMed Web of Science ®Google Scholar
• Roila F, Herrstedt J, Aapro M, et al. ESMO/MASCC Guidelines Working Group. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010;21(Suppl. 5):v232-43
   PubMed Web of Science ®Google Scholar
• Tonato M, Clark-Snow RA, Osoba D, et al. Emesis induced by low or minimal emetic risk chemotherapy. Support Care Cancer 2005;13:109-11
   PubMed Web of Science ®Google Scholar
• American Society of Clinical Oncology, Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006;24:2932-47. Erratum in: J Clin Oncol 2006;24:5341-2
   PubMed Web of Science ®Google Scholar
• Cohen L, de Moor CA, Eisenberg P, et al. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 2007;15:497-503
   PubMed Web of Science ®Google Scholar
• Molassiotis A, Saunders MP, Valle J, et al. A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer 2008;16:201-8
   PubMed Web of Science ®Google Scholar
• Petrella T, Clemons M, Joy A, et al. Identifying patients at high risk for nausea and vomiting after chemotherapy: the development of a practical validated prediction tool. II. Delayed nausea and vomiting. J Support Oncol 2009;7:W9-W16
   PubMedGoogle Scholar
• Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006;17:1441-9
   PubMed Web of Science ®Google Scholar
• Gebbia V, Cannata G, Testa A, et al. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial. Cancer 1994;74:1945-52
   PubMed Web of Science ®Google Scholar
• Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14:1570-7
   PubMed Web of Science ®Google Scholar
• Mantovani G, Macciò A, Curreli L, et al. Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin. Oncol Rep 1998;5:273-80
   PubMed Web of Science ®Google Scholar
• Navari RM. Prevention of emesis from multiple-day and high-dose chemotherapy regimens. J Natl Compr Canc Netw 2007;5:51-9
   PubMedGoogle Scholar
• Eglen RM, Lee CH, Smith WL, et al. Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo. Br J Pharmacol 1995;114:860-6
   PubMed Web of Science ®Google Scholar
• Eisenberg P, MacKintosh FR, Ritch P, et al. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol 2004;15:330-7
   PubMed Web of Science ®Google Scholar
• Wong EH, Clark R, Leung E, et al. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol 1995;114:851-9
   PubMed Web of Science ®Google Scholar
• Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009;10:115-24. Erratum in: Lancet Oncol 2010;11:226
   PubMed Web of Science ®Google Scholar
• Li Y, Wu X, Rojas C, et al. Palonosetron uniquely inhibits Substance P-mediated neuronal responses in rat nodose ganglia. Blood (ASH Annual Meeting Abstracts) 2009;114:abstr 4826
   Google Scholar
• Rojas C, Thomas AG, Alt J, et al. Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol 2010;626:193-9
   PubMed Web of Science ®Google Scholar
• Feinberg B, Gilmore J, Jackson J, et al. Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy. Support Care Cancer 2010;18(Suppl. 3):abstr
   Google Scholar
• Pirri C, Katris P, Trotter J, et al. Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational study. Support Care Cancer 2010 [Epub ahead of print]
   Google Scholar
• Roscoe JA, Bushunow P, Morrow GR, et al. Patient expectation is a strong predictor of severe nausea after chemotherapy: a University of Rochester Community Clinical Oncology Program study of patients with breast carcinoma. Cancer 2004;101:2701-8
   PubMed Web of Science ®Google Scholar